However, in the review by Russo et al. [70], the authors concluded that HDAC inhibitors “are emerging as very promising drugs for this purpose,” and that controlled clinical studies are needed to support a role of HDAC inhibitors in patients with thyroid cancer and who need more advanced treatment in addition to surgery and radioiodine. This evidence concerns the gene HDAC9 and thyroid gland carcinoma.